acute coronary syndrome

Alirocumab Neutralizes the Pro-inflammatory Risk of Oxidized Phospholipids After Acute Coronary Syndrome

By MedXY 12/25/2025

A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with alirocumab effectively mitigates this risk while significantly reducing biomarker levels.

Cardiology Emergency Medicine news

High-Sensitivity Cardiac Troponin Risk Stratification Safely Accelerates ED Discharge and Improves 1-Year Outcomes

By MedXY 12/24/2025

A secondary analysis of the HiSTORIC trial reveals that using high-sensitivity cardiac troponin for risk stratification significantly reduces ED length of stay and increases safe discharge rates for low- and intermediate-risk patients, with improved 1-year safety outcomes.

Cardiology news

Troponin Assay Transitions: Increased Clinical Burden Without Improved Cardiovascular Outcomes

By MedXY 12/24/2025

Switching from high-sensitivity troponin I to T significantly increases diagnoses of myocardial injury and hospital admissions without improving long-term cardiovascular outcomes, while low-threshold troponin I remains a safe tool for rapid rule-out.

Cardiology Clinical Updates news

Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis

By MedXY 12/18/2025

This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinical practice.

news Public Health Respiratory

Evaluating the 23-Valent Pneumococcal Polysaccharide Vaccine for Cardiovascular Event Prevention: Insights from a Landmark Randomized Trial

By MedXY 09/27/2025

A large randomized clinical trial demonstrated that the 23-valent pneumococcal polysaccharide vaccine (PPV23) did not significantly reduce fatal or nonfatal acute coronary syndrome and ischemic stroke among middle-aged adults at increased cardiovascular risk over seven years of follow-up.

Cardiology Clinical Updates news Specialties

Aspirin-Free Strategy in High Bleeding Risk PCI Patients: Insights from STOPDAPT-3 Subgroup Analysis

By MedXY 09/22/2025

In high bleeding risk patients undergoing PCI, aspirin-free prasugrel monotherapy fails to reduce major bleeding and shows increased myocardial infarction risk in ACS but not non-ACS patients, suggesting selective use post-PCI.

Cardiology

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY 09/22/2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

AI Cardiology Specialties

Advancing Acute Coronary Syndrome Care: ECG-Based Machine Learning Enhances Risk Stratification

By MedXY 08/16/2025

A prospective study shows that machine learning models trained on 12-lead ECG features outperform HEART score in predicting mortality among chest pain patients, improving risk-based care precision.